Teva Pharmaceutical Industries Limited (FRA:TEV)
Germany · Delayed Price · Currency is EUR | Market Cap | 31.94B +81.6% |
| Revenue (ttm) | 15.05B +4.4% |
| Net Income | 1.36B |
| EPS | 1.16 |
| Shares Out | n/a |
| PE Ratio | 23.53 |
| Forward PE | 14.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 855 |
| Open | 27.10 |
| Previous Close | 28.00 |
| Day's Range | 27.00 - 27.50 |
| 52-Week Range | 12.90 - 31.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About FRA:TEV
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
The company is seeing higher-margin growth, with EPS rising 72% year over year in the first quarter. The company's yearly guidance disappointed the markets.
Teva Pharmaceutical Industries (TEVA) Seeks FDA Approval for Ecopipam in Tourette Syndrome
Teva Pharmaceutical Industries (TEVA) Seeks FDA Approval for Ecopipam in Tourette Syndrome
TEVA Advances Pediatric Tourette Syndrome Treatment with New Drug Application
TEVA Advances Pediatric Tourette Syndrome Treatment with New Drug Application
Teva Pharmaceutical Industries Ltd (TEVA) Shares Fall 3.3% -- GF Value Says Still Overvalued
Teva Pharmaceutical Industries Ltd (TEVA) Shares Fall 3.3% -- GF Value Says Still Overvalued
Teva submits NDA for Ecopipam to FDA
The company states: “Teva (TEVA) Pharmaceutical announced the submission of a New Drug Application to the U.S. Food and Drug Administration for ecopipam, a first-in-class investigational therapy for t...
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug A...
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quar...
Analyst Maintains Buy Rating on Teva (TEVA) Amid Recent Performance Concerns
Analyst Maintains Buy Rating on Teva (TEVA) Amid Recent Performance Concerns
Jefferies continues to like Teva after recent pullback
Noting that Teva (TEVA) has underperformed the last two weeks, Jefferies analyst Dennis Ding explained that a “big part of the weakness is due to macro,” but also says it…
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Teva has a handful of new biosimilars on the market, with more to come. Those assets will doubtlessly deliver some top-line growth.
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
CHICAGO--(BUSINESS WIRE)--Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology comp...
Teva Acquires Emalex For $700 Mln; Ecopipam NDA Planned In H2 2026
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) announced the completion of its acquisition of Emalex Biosciences for a consideration of $700 million, with the potential for up to an additio...
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva's acquisition of Emalex Biosciences, strengthening it...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.6% Gain -- GF Value $20. ...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.6% Gain -- GF Value $20.78 vs Price $34.45
Teva put volume heavy and directionally bearish
Bearish flow noted in Teva (TEVA) with 4,549 puts trading, or 3x expected. Most active are 6/12 weekly 33.5 puts and Sep-26 40 calls, with total volume in those strikes…
Teva Presents Positive Data For AUSTEDO And AUSTEDO XR In Treating Tardive Dyskinesia
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), a pharmaceuticals company, on Friday announced new IMPACT-TD and RIM-TD data evaluating AUSTEDO and AUSTEDO XR in treating Tardive dyskinesia...
Teva presents positive long-term study data for Austedo
Teva (TEVA) announced new data highlighting symptom improvement from treatment with Austedo and Austedo XR in patients with tardive dyskinesia. Findings from the real-world IMPACT-TD study evaluated p...
Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data t...
Teva Pharmaceutical Industries Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a disciplined growth strategy centered on innovation, generics expansion, and capital allocation, with major product launches and pipeline readouts expected through 2028. The company’s transformation into a biopharma leader is reinforced by robust execution, undervalued assets, and a strong outlook for long-term value creation.
Teva Reports Positive Real-World Data For AUSTEDO And AUSTEDO XR In Treating Huntington's Chorea
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), a pharmaceuticals company, on Friday announced new data from the real-world study evaluating AUSTEDO and AUSTEDO XR in treating Huntington's ...
TEVA Unveils Positive Results in Real-World Study of AUSTEDO for Huntington's Disease
TEVA Unveils Positive Results in Real-World Study of AUSTEDO for Huntington's Disease
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
Teva announces new data on AUSTEDO tablets, AUSTEDO XR tablets
Teva (TEVA) Pharmaceuticals announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington’s disease ch...
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington’s Disease Chorea
New real-world survey data reveal the daily impact of Huntington’s disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of careg...
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data f...